Isis Pharmaceuticals, Inc. Message Board
-
Schoenebaum noted "the company’s CFO yesterday explicitly said that 1Q consensus sales estimates need to come down. Previously, the company had commented that 1Q sales would be sequentially below 4Q sales – but the company appears to be saying that the decline could be far more significant than the Street is currently estimating."
Dendreon has indicated that it expects Provenge to return to positive growth after Q1, at which stage a direct-to-consumer advertising campaign is expected to begin. Schoenebaum’s comments appeared to reflect a broadly held view, however, when he noted that limited visibility on future performance and a competitive impact that will only intensify moving forward had driven his move away from a 'buy' rating -
When options get tight, you must know that time for get back or cover.
-
Nothing can bring this down.....Godfathers are now working on it.
-
Trend is up now !
-
Otherwise it would have been $6 by now..
-
This is DNDN after American Associations of Urologist meeting data presentations.
- Reply to
As long as Urologist endrose Clinical Data at AAU meeting Provenge not worried
by dinepat203 •May 14, 2013 12:14 PMSales would pick up by Q2 now
-
I got it ! you short at 3.99 and covered at 4.09 !
Next you could short at 4.99 - Reply to
As long as Urologist endrose Clinical Data at AAU meeting Provenge not worried
by dinepat203 •May 14, 2013 12:14 PMLife is back at DNDN and with EU collaboration DNDN will remain as wallstreet darling in coming days.
-
May be in your day dream
- Reply to
As long as Urologist endrose Clinical Data at AAU meeting Provenge not worried
by dinepat203 •May 14, 2013 12:14 PMThese presentations at AUA provide the medical community with possible new insight on the role of PROVENGE in men with advanced prostate cancer
-
DNDN need not to worry about Zytiga or Xtandi competitions.
- Reply to
DNDN found solid base after AUA Annual Meeting- Expect Godfather at Door..
by dinepat203 •May 14, 2013 11:47 AMWebsite updated
- Reply to
DNDN found solid base after AUA Annual Meeting- Expect Godfather at Door..
by dinepat203 •May 14, 2013 11:47 AMNews Provided by Acquire Media
-
PROVENGE research presented at this year's AUA Annual Meeting reflects Dendreon's ongoing commitment to men in need of new treatment options for advanced prostate cancer," said Mark Frohlich, M.D.,
- Reply to
Breaking the SPEED BARRIER ...DNDN Cancer Drug back in action 3 trials results..
by dinepat203 •May 14, 2013 10:55 AMThink !!! are they stupid to say "PROVENGE is an innovative treatment option that uses a patient's own cells to activate the immune system to fight the disease, and these data reinforce what we have seen in the clinical setting."
- Reply to
Breaking the SPEED BARRIER ...DNDN Cancer Drug back in action 3 trials results..
by dinepat203 •May 14, 2013 10:55 AM• Abstract #960: E. David Crawford, M.D., professor of surgery, urology, and radiation oncology, and head of the section of urologic oncology at the University of Colorado Denver School of Medicine, will present a poster titled "Optimal Timing for Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Sequencing and Identifying Parameters of Early Progression with Sipuleucel-T:" In the Phase 3 IMPACT trial, a retrospective subgroup analysis suggested a greater PROVENGE treatment effect in those patients with a lower baseline PSA. These data were recently published in the international journal, Urology.
• Abstract #971: Thomas Gardner, M.D., associate professor in the Department of Microbiology and Immunology at Indiana University School of Medicine, will present a poster titled "Safety and Changes in Laboratory Parameters Associated with Sipuleucel-T in Patients with Metastatic Castration-Resistant Prostate Cancer: Phase II ProACT study:" A Phase II study evaluated immune responses and overall survival of patients receiving PROVENGE manufactured with different concentrations of antigen. Increased globulin protein and transient increased eosinophil counts were consistent with previous studies and positively correlated with immune response and overall survival. The safety profile of PROVENGE was consistent with that observed in previous clinical trials.
• Abstract #972: Matthew Cooperberg, M.D., assistant professor of urology, epidemiology and biostatistics, University of California, San Francisco, will present a poster titled "Treatment Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Prior to Receiving Sipuleucel-T: Data from PROCEED:" In a Phase IV registry study, data on patients enrolled before they received PROVENGE provides a window into current treatment patterns for patients with advanced prostate cancer and will continue to yield important information that can be used to track trends in patient demographics and treatment prior to and after receiving PROVENGE.
"These presentations at AUA provide the medical community with possible new insight on the role of PROVENGE in men with advanced prostate cancer," said E. David Crawford, M.D., professor of surgery, urology, and radiation oncology, and head of the section of urologic oncology at the University of Colorado, Denver School of Medicine -
DNDN style..
- Reply to
SHOW ME ANY COMPANY WHICH HAS 300M REVENUE AND MKT CAP 600M
by dinepat203 •May 14, 2013 9:59 AMImagine 100,000 shares got sold in one stroke.
-
Now women and children please off board..